Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

30 Sept 2019

Abstract excerpt

Key Points CXCR4 S338X clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4 S338X clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Gastrointestinal Tumor Research and Treatment
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31570491
DOI: 10.1182/bloodadvances.2019000635

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaPMID 31570491Read ↗

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.Semantic proximity Read ↗

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.Semantic proximity Read ↗

Distinct immune and genomic signatures predict resistance to ibrutinib therapy in Waldenström macroglobulinemiaSemantic proximity Read ↗

Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.Semantic proximity Read ↗

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.Semantic proximity Read ↗

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsSemantic proximity Read ↗

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.Semantic proximity Read ↗

How to Sequence Therapies in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.